21 reports

We track medical devices that are in development related to nearly ## markets (ie, cardiovascular devices, dental devices etc) that we cover.

  • In Vitro Diagnostics
  • Targeted Therapy
  • Spain
  • United States
  • Biokit S.A.

s pumps and devices business.

  • Healthcare
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.

We track medical devices that are in development related to nearly ## markets (i. e., cardiovascular devices, dental devices etc) that we cover.

  • Anti-Infective
  • Clinical Trial
  • Targeted Therapy
  • Transplantation
  • Roche Group
  • NOVARTIS AG
  • PIPELINE BY NOVARTIS AG, H2 2018

NovelMed also provides Inflammin, a cardiovascular device that converts the blood into a form that resists AP activation during cardiac procedures.

  • Ophthalmology
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Alexion Pharmaceuticals, Inc.

GlobalData Women' s Health Genito Urinary System And Sex Hormones Dermatology ## ##, ##. ## ## ##, ##. ## ## ##, ##. ## Male Health ## ##. ## Hormonal Disorders ## ##. ## Toxicology ## ##. ## Other Diseases ## NA Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 LIGAND PHARMACEUTI

  • Medical Biotechnology
  • Targeted Therapy
  • United States
  • Company
  • Ligand Pharmaceuticals Incorporated

NovelMed also provides Inflammin, a cardiovascular device that converts the blood into a form that resists AP activation during cardiac procedures.

  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.
  • eculizumab biosimilar
  • PIPELINE BY NOVARTIS AG, H1 2018

NovelMed also provides Inflammin, a cardiovascular device that converts the blood into a form that resists AP activation during cardiac procedures.

  • Monoclonal Antibody
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Alexion Pharmaceuticals, Inc.

We track medical devices that are in development related to nearly ## markets (ie, cardiovascular devices, dental devices etc) that we cover.

  • Clinical Trial
  • Diagnostics
  • Point Of Care Testing
  • Targeted Therapy
  • Grifols, S.A.
  • eculizumab biosimilar
  • PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - PIPELINE BY NOVELMED THERAPEUTICS INC, H1 2018

NovelMed also provides Inflammin, a cardiovascular device that converts the blood into a form that resists AP activation during cardiac procedures.

  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • Achillion Pharmaceuticals, Inc.

THE DEVICE IS AVAILABLE EXCLUSIVELY FOR OMNITROPE.

  • Targeted Therapy
  • North America
  • United States
  • Market Size
  • Sandoz Inc.

We track medical devices that are in development related to nearly ## markets (ie, cardiovascular devices, dental devices etc) that we cover.

  • Cancer
  • Genetic Testing
  • Hospital
  • Targeted Therapy
  • Guardant Health, Inc.

WE TRACK MEDICAL DEVICES THAT ARE IN DEVELOPMENT RELATED TO NEARLY ## MARKETS (IE, CARDIOVASCULAR DEVICES, DENTAL DEVICES ETC) THAT WE COVER.

  • Autoimmune Disease
  • Biomarker
  • Targeted Therapy
  • United States
  • Myriad Genetics, Inc.

We track medical devices that are in development related to nearly ## markets (ie, cardiovascular devices, dental devices etc) that we cover.

  • Anti-Infective
  • Diagnostics
  • Monoclonal Antibody
  • Targeted Therapy
  • Roche Group
  • PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - PIPELINE BY NOVELMED THERAPEUTICS INC, H2 2019

NovelMed also provides Inflammin, a cardiovascular device that converts the blood into a form that resists AP activation during cardiac procedures.

  • Medical Biotechnology
  • Pharmaceutical
  • Targeted Therapy
  • United States
  • Product Initiative

We track medical devices that are in development related to nearly ## markets (ie, cardiovascular devices, dental devices etc) that we cover.

  • In Vitro Diagnostic Reagent
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Grifols, S.A.

NOVELMED ALSO PROVIDES INFLAMMIN, A CARDIOVASCULAR DEVICE THAT CONVERTS THE BLOOD INTO A FORM THAT RESISTS AP ACTIVATION DURING CARDIAC PROCEDURES.

  • Neurological Disorder
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative

We track medical devices that are in development related to nearly ## markets (ie, cardiovascular devices, dental devices etc) that we cover.

  • Medical Biotechnology
  • Ovarian Cancer
  • Targeted Therapy
  • United States
  • Pfizer Inc.

We track medical devices that are in development related to nearly ## markets (ie, cardiovascular devices, dental devices etc) that we cover.

  • Cancer
  • Targeted Therapy
  • Type 1 Diabetes
  • United States
  • Company

We track medical devices that are in development related to nearly ## markets (ie, cardiovascular devices, dental devices etc) that we cover.

  • Leukemia
  • Targeted Therapy
  • Therapy
  • United States
  • Pfizer Inc.

NovelMed also provides Inflammin, a cardiovascular device that converts the blood into a form that resists AP activation during cardiac procedures.

  • Eye Disease
  • Monoclonal Antibody
  • Ophthalmology
  • Targeted Therapy
  • Allergan plc

In May 2015, Bristol -Myers Squib registered a Phase II trial of apixaban to evaluate the safety and efficacy of apixaban in patients who underwent cardiovascular implantable device (CIED) procedure.

  • Research And Development
  • Targeted Therapy
  • Therapy
  • United States
  • Bristol-Myers Squibb Company